A Randomized, Phase III Trial of ABI-007 [albumin-bound paclitaxel; ABRAXANE; Abraxis BioScience] and Carboplatin Compared With Taxol [paclitaxel; Bristol-Myers Squibb] and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Randomized, Phase III Trial of ABI-007 [albumin-bound paclitaxel; ABRAXANE; Abraxis BioScience] and Carboplatin Compared With Taxol [paclitaxel; Bristol-Myers Squibb] and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Oct 2016 Results of post-hoc analysis assessing clinical outcomes from patients with squamous histology (n=450) published in the Journal of Thoracic Oncology.
    • 02 Jun 2015 Results published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top